Alison MD - Freeline Therapeutics Sr Officer
| FRLNDelisted Stock | USD 4.31 0.28 6.10% |
Insider
Alison MD is Sr Officer of Freeline Therapeutics Holdings
| Phone | 44 14 3890 6870 |
| Web | https://www.freeline.life |
Freeline Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.555) % which means that it has lost $0.555 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0126) %, meaning that it created substantial loss on money invested by shareholders. Freeline Therapeutics' management efficiency ratios could be used to measure how well Freeline Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Freeline Therapeutics Holdings currently holds 5.92 M in liabilities with Debt to Equity (D/E) ratio of 0.64, which is about average as compared to similar companies. Freeline Therapeutics has a current ratio of 3.61, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Freeline Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| LaBella MS | ZyVersa Therapeutics | 66 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 69 | |
| Daren Ure | Hepion Pharmaceuticals | N/A | |
| Nandan BS | Immix Biopharma | 62 | |
| Launa Aspeslet | Hepion Pharmaceuticals | N/A | |
| CPA CTP | Cns Pharmaceuticals | 44 | |
| BSc BSc | Hepion Pharmaceuticals | 66 | |
| John Cini | Sonnet Biotherapeutics Holdings | 71 | |
| Stephen MD | Hepion Pharmaceuticals | N/A | |
| Donald Picker | Cns Pharmaceuticals | 78 | |
| Waldemar Priebe | Cns Pharmaceuticals | N/A | |
| MD FACP | Sonnet Biotherapeutics Holdings | 66 | |
| DSc MSE | Immix Biopharma | 75 | |
| MBA MD | Immix Biopharma | 49 | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| Sharen Pyatetskaya | Hepion Pharmaceuticals | ||
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| Jay Cross | Sonnet Biotherapeutics Holdings | 53 | |
| Gabriel BA | Immix Biopharma | 37 | |
| JD MBA | Immix Biopharma | N/A | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
Management Performance
| Return On Equity | -1.01 | |||
| Return On Asset | -0.56 |
Freeline Therapeutics Leadership Team
Elected by the shareholders, the Freeline Therapeutics' board of directors comprises two types of representatives: Freeline Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Freeline. The board's role is to monitor Freeline Therapeutics' management team and ensure that shareholders' interests are well served. Freeline Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Freeline Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Amit MD, Independent Founder | ||
| Markus Horer, CTO Founder | ||
| Henning Stennicke, Chief Officer | ||
| Naomi Aoki, Senior Relations | ||
| Michael JD, CEO Director | ||
| James Bircher, Chief Officer | ||
| Amy Spandau, Interim Finance | ||
| Pamela MD, Chief Officer | ||
| Arne Naeveke, VP Communications | ||
| Alison MD, Sr Officer | ||
| Nicole SPHR, Chief Officer | ||
| Paul Schneider, Chief Officer |
Freeline Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Freeline Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.01 | |||
| Return On Asset | -0.56 | |||
| Current Valuation | 2.78 M | |||
| Shares Outstanding | 4.36 M | |||
| Shares Owned By Insiders | 1.09 % | |||
| Shares Owned By Institutions | 45.88 % | |||
| Number Of Shares Shorted | 23.93 K | |||
| Price To Book | 0.94 X | |||
| Price To Sales | 45.40 X | |||
| Revenue | 622 K |
Pair Trading with Freeline Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Freeline Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Freeline Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Freeline Stock
| 0.71 | MCD | McDonalds Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.59 | CAT | Caterpillar Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.57 | DD | Dupont De Nemours Fiscal Year End 4th of February 2025 | PairCorr |
| 0.53 | SSNLF | Samsung Electronics | PairCorr |
| 0.48 | IBM | International Business Fiscal Year End 22nd of January 2025 | PairCorr |
The ability to find closely correlated positions to Freeline Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Freeline Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Freeline Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Freeline Therapeutics Holdings to buy it.
The correlation of Freeline Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Freeline Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Freeline Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Freeline Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Freeline Stock
If you are still planning to invest in Freeline Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Freeline Therapeutics' history and understand the potential risks before investing.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |